Abstract
KRAS-mutations are present in 25-30% of the most common form of lung cancer, lung adenocarcinoma (LUAD), and KRASG12C mutations account for 40% of KRAS-mutations in LUAD. Recent development of covalent GDP-KRASG12C inhibitors (G12Ci) have reignited efforts to target the once “undruggable” protein. Preclinical studies have identified mechanisms of adaptive resistance in cell lines. However, patient-derived xenografts (PDX) and xenograft-derived organoids (XDO) have not yet been extensively used to study mechanisms of primary and acquired resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
